Sridhar Natesan

List of Publications by Year
in descending order

48 papers	2,711 citations	257450 24 h-index	302126 39 g-index
56 all docs	56 docs citations	56 times ranked	3605 citing authors

#	Article	IF	Citations
1	Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry,the, 2020, 7, 64-77.	7.4	506
2	Dissociation between In Vivo Occupancy and Functional Antagonism of Dopamine D2 Receptors: Comparing Aripiprazole to Other Antipsychotics in Animal Models. Neuropsychopharmacology, 2006, 31, 1854-1863.	5.4	194
3	Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?. British Journal of Psychiatry, 2016, 209, 361-365.	2.8	193
4	Antipsychotics: Mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology, 2020, 172, 107704.	4.1	180
5	Effect of Chronic Antipsychotic Treatment on Brain Structure: A Serial Magnetic Resonance Imaging Study with Ex Vivo and Postmortem Confirmation. Biological Psychiatry, 2011, 69, 936-944.	1.3	166
6	Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. Nature Communications, 2020, 11, 246.	12.8	148
7	Contrasting Effects of Haloperidol and Lithium on Rodent Brain Structure: A Magnetic Resonance Imaging Study with Postmortem Confirmation. Biological Psychiatry, 2012, 71, 855-863.	1.3	113
8	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinsonâ€™s disease. Brain, 2015, 138, 3003-3015.	7.6	100
9	Altered PDE10A expression detectable early before symptomatic onset in Huntingtonâ€™s disease. Brain, 2015, 138, 3016-3029.	7.6	90
10	Reduced Cortical Volume and Elevated Astrocyte Density in Rats Chronically Treated With Antipsychotic Drugsâ€"Linking Magnetic Resonance Imaging Findings to Cellular Pathology. Biological Psychiatry, 2014, 75, 982-990.	1.3	85
11	Microglial activation in the rat brain following chronic antipsychotic treatment at clinically relevant doses. European Neuropsychopharmacology, 2015, 25, 2098-2107.	0.7	77
12	The Dopamine Stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)-1-propyl-piperidine (ACR16) Show High in Vivo D2 Receptor Occupancy, Antipsychotic-Like Efficacy, and Low Potential for Motor Side Effects in the Rat. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 810-818.	2.5	75
13	A Method for Tapering Antipsychotic Treatment That May Minimize the Risk of Relapse. Schizophrenia Bulletin, 2021, 47, 1116-1129.	4.3	69
14	Amisulpride the â€˜atypicalâ€™ atypical antipsychotic â€" Comparison to haloperidol, risperidone and clozapine. Schizophrenia Research, 2008, 105, 224-235.	2.0	64
15	Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. Molecular Psychiatry, 2021, 26, 2562-2576.	7.9	60
16	The Effects of Antipsychotic Treatment on Presynaptic Dopamine Synthesis Capacity in First-Episode Psychosis: A Positron Emission Tomography Study. Biological Psychiatry, 2019, 85, 79-87.	1.3	54
17	The antipsychotic potential of l-stepholidineâ€"a naturally occurring dopamine receptor D1 agonist and D2 antagonist. Psychopharmacology, 2008, 199, 275-289.	3.1	53
18	Regulation of dopaminergic function: an [18F]-DOPA PET apomorphine challenge study in humans.. Translational Psychiatry, 2017, 7, e1027-e1027.	4.8	53

#	Article	IF	Citations
19	Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human. Journal of Nuclear Medicine, 2014, 55, 595-601.	5.0	50
20	Evaluation of N-Desmethylclozapine as a Potential Antipsychoticâ€"Preclinical Studies. Neuropsychopharmacology, 2007, 32, 1540-1549.	5.4	47
21	Dynamic regulation of dopamine and serotonin responses to salient stimuli during chronic haloperidol treatment. International Journal of Neuropsychopharmacology, 2011, 14, 1327-1339.	2.1	46
22	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. Journal of the Neurological Sciences, 2016, 368, 243-248.	0.6	37
23	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [¹¹C]IMA107. American Journal of Psychiatry, 2016, 173, 714-721.	7.2	33
24	The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. Translational Psychiatry, 2021, 11, 393.	4.8	27
25	Partial agonists in schizophrenia â€" why some work and others do not: insights from preclinical animal models. International Journal of Neuropsychopharmacology, 2011, 14, 1165-1178.	2.1	24
26	Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways. Translational Psychiatry, 2013, 3, e208-e208.	4.8	24
27	Effects of the dopamine stabilizer, OSU-6162, on brain stimulation reward and on quinpirole-induced changes in reward and locomotion. European Neuropsychopharmacology, 2009, 19, 416-430.	0.7	21
28	Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [11C]MP-10 PET rodent imaging study with ex vivo confirmation. Translational Psychiatry, 2014, 4, e376-e376.	4.8	16
29	Chronic exposure to haloperidol and olanzapine leads to common and divergent shape changes in the rat hippocampus in the absence of grey-matter volume loss. Psychological Medicine, 2016, 46, 3081-3093.	4.5	14
30	Contrasting loxapine to its isomer isoloxapineâ€"the critical role of in vivo D2 blockade in determining atypicality. Schizophrenia Research, 2005, 77, 189-199.	2.0	12
31	Effects of chronic antipsychotic drug exposure on the expression of Translocator Protein and inflammatory markers in rat adipose tissue. Psychoneuroendocrinology, 2018, 95, 28-33.	2.7	12
32	Radiosynthesis, ex vivo and in vivo evaluation of [11C]preclamol as a partial dopamine D2 agonist radioligand for positron emission tomography. Synapse, 2006, 60, 314-318.	1.2	11
33	Haloperidol modulates noradrenergic responses to aversive stimulation depending on treatment duration. Behavioural Brain Research, 2011, 221, 311-313.	2.2	11
34	Modeling chronic olanzapine exposure using osmotic minipumps: Pharmacological limitations. Pharmacology Biochemistry and Behavior, 2011, 100, 86-89.	2.9	11
35	The magnitude and heterogeneity of antidepressant response in depression: A meta-analysis of over 45,000 patients. Journal of Affective Disorders, 2020, 276, 991-1000.	4.1	11
36	Effects of chronic exposure to haloperidol, olanzapine or lithium on SV2A and NLGN synaptic puncta in the rat frontal cortex. Behavioural Brain Research, 2021, 405, 113203.	2.2	10

#	Article	IF	Citations
37	Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study. Psychopharmacology, 2022, 239, 3439-3445.	3.1	8
38	Quantification of l-stepholidine in rat brain and plasma by high performance liquid chromatography combined with fluorescence detection. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 850, 544-547.	2.3	3
39	Antipsychotic therapy over half a century: a tale of discovery from chlorpromazine to aripiprazole. The National Medical Journal of India, 2012, 25, 193-5.	0.3	1
40	Time to re-evaluate the risks and benefits of valproate and a call for action. British Journal of Psychiatry, 2022, 221, 711-713.	2.8	1
41	PARTIAL AGONISTS IN SCHIZOPHRENIA â€“ WHY SOME SUCCEED AND OTHERS DON'T. INSIGHTS FROM PRECLINICAL COMPARISONS. Schizophrenia Research, 2010, 117, 383-384.	2.0	0
42	Reply to: Lithium and the Expanding Brain. Biological Psychiatry, 2012, 72, e19.	1.3	0
43	T193. CHRONIC HALOPERIDOL TREATMENT INDUCES SIGNIFICANT CHANGES IN MICROGLIA AND IN THE EXPRESSION OF THE 18 KDA TRANSLOCATOR PROTEIN TSPO IN NAIVE ADULT RAT BRAINS. Schizophrenia Bulletin, 2018, 44, S191-S191.	4.3	0
44	40.3 MATERNAL IMMUNE ACTIVATION AND CHRONIC HALOPERIDOL INTERACT TO INCREASE MICROGLIAL ACTIVATION IN VIVO: DO ANTIPSYCHOTICS INFLAME THE BRAIN?. Schizophrenia Bulletin, 2018, 44, S65-S65.	4.3	0
45	179. Effects of Chronic Haloperidol Treatment on Brain Volume in a Rat Model in of Infection-Mediated Neurodevelopmental Disorders. Biological Psychiatry, 2019, 85, S74.	1.3	0
46	Region-specific increases in the expression of translocator protein 18kDa (TSPO) after chronic exposure to haloperidol in naÃ¯ve adult rats. European Neuropsychopharmacology, 2019, 29, S252.	0.7	0
47	O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS. Schizophrenia Bulletin, 2020, 46, S28-S28.	4.3	0
48	Synaptic Dysfunction in Schizophrenia and the Effects of Treatment: Complementary in Vivo Clinical and Preclinical Studies. Biological Psychiatry, 2021, 89, S34-S35.	1.3	0